For this project, doctors and data miners are specifically focusing on lung cancer patients | ScienceDaily
By flagging things like recent lab tests, radiology visits, or patient-reported symptoms, Penn’s team is hoping to come up with a formula that will predict when a patient is likely to end up visiting the emergency room. Right now, the formula can predict an estimated one out of every three ER visits, giving doctors the chance to take action before a patient gets to that point.
Objective: To perform a first-time analysis of the cost-effectiveness (CE) literature on chemotherapies, of all types, in cancer, in terms of trends and change over time, including the influence of industry funding.
Conclusions: This analysis demonstrates clear trends in how the CE cancer research is presented to the practicing community, including in relation to journals, study designs, authorship and consultation, together with increased financial sponsorship by pharmaceutical industries, which may be more influencing study outcomes than other funding sources.
Guillon, A. et al. Critical Care. Published online: 27 January 2017
Bald heads may soon not be a sign that identifies a cancer patient receiving treatment. Indeed, therapies for cancer patients are improving dramatically leading to increased survival rates, and most are associated with a different toxicity profile. Recently, antibody-based therapy has transformed the therapeutic landscape and biology of non-small cell lung cancer (NSCLC) and other solid tumors. This may also reshuffle the playing cards for an intensive care unit (ICU) admission policy due to improved outcomes.
In November 2016, the results of the KEYNOTE-024 trial showed for the first time the superiority of immunotherapy over chemotherapy as first-line treatment for NSCLC . In this phase 3 trial, a humanized monoclonal antibody (mAb) against programmed death 1 (PD-1) was tested in patients who had previously untreated advanced NSCLC. The clinical trial was stopped by the safety monitoring committee on the basis of substantial clinical benefit of immunotherapy, and patients remaining in the chemotherapy group were switched to receive immunotherapy.
Young and middle-aged patients with colon cancer are nearly two to eight times more likely to receive postoperative chemotherapy than older patients, yet there seems to be no added survival benefits for these patients | ScienceDaily
Colorectal cancer is the third leading cause of cancer death in the U.S. There were more than 49,000 deaths in 2016, and more than 134,000 new cases are expected this year. While incidence and mortality rates among adults age 50 and older have decreased recently in the U.S., the same trend hasn’t been observed for patients 20 to 49. Treatment options remain to be defined for patients with young-onset colon cancer and their effects on prognosis are unclear.
The National Lung Cancer Audit annual report 2016, commissioned by the Healthcare Quality Improvement Partnership (HQIP), shows an encouraging rise in survival as more patients receive life-prolonging treatments.
The report covers patients with lung cancer first diagnosed in 2015. It says there was a 7% increase in the number of people diagnosed with lung cancer surviving for longer than one year – rising from 31% to 38% in the five-year period from 2010 to 2015.
In addition, 60% of lung cancer patients received anti-cancer treatment such as chemotherapy, radiotherapy or surgery, meeting the target set out in the 2015 annual audit report.
Better GP access to cancer diagnostic tools would benefit doctors and patients, says RCGP |via OnMedica
The Royal College of GPs has welcomed a £5 million grant aimed at giving GPs better access to cancer diagnostic tools. Cancer Research UK (CRUK), which is funding the research project, said having more effective ways to diagnose cancer in GP surgeries would save both doctors’ and patients’ time, and reduce anxiety for patients.
The charity announced its £5 million funding for the “revolutionary” CanTest project as part of its Catalyst Award, which it said “aims to help researchers from around the world deliver trailblazing progress in their field with long-lasting results”. CanTest will investigate and develop new ways for GPs, physician’s assistants and nurse practitioners to diagnose cancer in GP surgeries. It will assess the accuracy, cost effectiveness and suitability of a range of diagnostic methods and tools, with the aim of cutting both the wait for diagnosis and the number of referrals.
This is the 12th report on the clinical component (process of care) of the National Lung Cancer Audit. It publishes national and named team results on the quality of lung cancer care for patients diagnosed between 1 January and 31 December 2015. The key findings include a 7% rise in one-year survivorship since 2010.
Objectives: The aim of this study was to estimate lowest possible treatment costs for four novel cancer drugs, hypothesising that generic manufacturing could significantly reduce treatment costs.
Conclusions: Our findings demonstrate that affordable drug treatment costs are possible for novel cancer drugs, suggesting that new therapeutic options can be made available to patients and doctors worldwide. Assessing treatment cost estimations alongside cost-effectiveness evaluations is an important area of future research.
The biggest leap in diagnosing prostate cancer “in decades” has been made using new scanning equipment, say doctors and campaigners | BBC News
The trial, at 11 hospitals in the UK, used multi-parametric MRI on men with high PSA levels. It showed 27% of the men did not need a biopsy at all. And 93% of aggressive cancers were detected by using the MRI scan to guide the biopsy compared with just 48% when the biopsy was done at random.
Dr Ahmed, who works at University College London Hospitals, told the BBC News website:
“This is a significant step-change in the way we diagnose prostate cancer. We have to look at the long-term survival, but in my opinion by improving the detection of important cancers that are currently missed we could see a considerable impact. But that will need to be evaluated in future studies, and we may have to wait 10 to 15 years.”